Plain-English translation of NCT06947044 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing whether giving red blood cell transfusions to keep your hemoglobin (a protein in red blood cells) closer to normal levels helps reduce bleeding problems in patients with acute leukemia. You would be randomly assigned to receive either more frequent transfusions to keep your hemoglobin above 110 g/L, or standard transfusions to keep it above 70–80 g/L. The study will measure blood markers related to bleeding risk under both approaches.
Patients with acute leukemia often develop low red blood cell counts and bleeding problems during chemotherapy. Researchers want to know if raising blood levels closer to normal through more frequent transfusions can reduce dangerous bleeding without causing other harm.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two transfusion strategies during your leukemia treatment. One group will receive transfusions to keep hemoglobin above 110 g/L (more frequent), and the other will follow standard practice with transfusions to keep it above 70–80 g/L (less frequent). Researchers will regularly monitor your blood work and look for bleeding complications to understand how each strategy affects your bleeding risk.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Canada